Medtronic and IBM's Watson Health unit outlined a tool to predict whether a diabetic person will have low glucose even within an upcoming 1- to 4-hour window.
The feature, called IQcast, is part of the Sugar.IQ personal diabetes app, which is available on Apple's iOS platform. The tool uses IBM's artificial intelligence and Medtronics diabetes devices.
For IBM, the Medtronic collaboration is part of a broader wellness technology push leading up to CES 2019. IBM CEO Ginni Rometty is giving a keynote speech revolving in part around AI. Also last month, IBM highlighted how it was combining AI and fingernail sensors to better monitor health and disease.
Medtronic has been partnering with various technology companies to layer in more analytics. Medtronic has partnerships with IBM, Apple, and Fitbit to name a few.
According to the companies, the IQcast feature analyzes various signals to assess the likelihood of a low glucose event. The Sugar.IQ app combines various metrics and tries to assess patterns as people manage diabetes including insulin injections.